{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:40:38Z","timestamp":1760060438711,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation Committee","doi-asserted-by":"publisher","award":["7252108","2024-I2M-C&T-B-006"],"award-info":[{"award-number":["7252108","2024-I2M-C&T-B-006"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences","award":["7252108","2024-I2M-C&T-B-006"],"award-info":[{"award-number":["7252108","2024-I2M-C&T-B-006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: This study was aimed to comprehensively investigate the clinical and molecular characteristics, treatments, and outcomes of young patients with lung cancer in the new era of cancer treatment. Methods: Clinical data from patients aged 18 to 45 with lung cancer, treated at our hospital from January 2014 through January 2024, were systematically collected and analyzed. Results: This study enrolled a total of 343 patients, with a predominance of females, never-smokers, and those diagnosed at an advanced stage. Adenocarcinoma was the most common histology (72.0%), and rare tumors could also be seen in young patients, such as pulmonary sarcomatoid carcinoma and pulmonary mucoepidermoid carcinoma. The mutation rate of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in NSCLC patients were 35.9% (111\/309) and 14.2% (44\/309), respectively. PD-L1 expression was assessed in 55 patients, with 14 showing high expression (\u226550%) and 24 showing negative expression (&lt;1%). The median overall survival (mOS) for the entire cohort was 80.2 months, with a 5-year survival rate of 55.7%. For patients with stage I, II, and III disease, the mOS had not yet been reached, whereas the mOS for stage IV patients was 39.7 months. Targeted therapy, particularly second-generation ALK tyrosine kinase inhibitors (TKIs), significantly improved the prognosis of patients with driver gene mutations. Chemotherapy combined with immunotherapy was beneficial for patients with progressive disease or driver gene negativity in NSCLC and was associated with improved OS in small cell lung cancer (SCLC). Female, family history of lung cancer, positive driver genes, and first-line use of second-generation ALK-TKIs are independent prognostic factors in young patients with advanced NSCLC. Conclusions: Our findings highlight the importance of early diagnosis, targeted therapy, and immunotherapy in improving outcomes for young patients with lung cancer.<\/jats:p>","DOI":"10.3390\/curroncol32090489","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:24:41Z","timestamp":1756805081000},"page":"489","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis"],"prefix":"10.3390","volume":"32","author":[{"given":"Xiaoyi","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjie","family":"Li","sequence":"additional","affiliation":[{"name":"Biomedical Engineering Facility of National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanxian","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Baoding No.1 Hospital, Baoding 071000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_3","first-page":"139","article-title":"Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_4","first-page":"565","article-title":"Morbidity situation of lung cancer in China\u2014Japan Friendship Hospital from 2005 to 2014","volume":"19","author":"Peng","year":"2016","journal-title":"Chin. Gen. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-024-01623-9","article-title":"Global cancer statistics for adolescents and young adults: Population based study","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s12276-020-00493-8","article-title":"Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer","volume":"52","author":"Cho","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.21037\/atm.2019.01.69","article-title":"Clinicopathological characteristics and treatment strategies for young lung cancer patients","volume":"7","author":"Yoneyama","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/jayao.2021.0069","article-title":"Lung Cancer Versus \u201cYoung Cancer\u201d: Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?","volume":"11","author":"Bratova","year":"2022","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamaoncol.2015.4479","article-title":"Young Patients with Lung Cancer\u2014An Understudied Population","volume":"2","author":"West","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00408-019-00294-5","article-title":"Lung Cancer in the Young","volume":"198","author":"Ruiz","year":"2020","journal-title":"Lung"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","article-title":"Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non\u2013Small-Cell Lung Cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jtho.2016.03.023","article-title":"Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base","volume":"11","author":"Arnold","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pulmoe.2021.08.010","article-title":"Lung cancer in young patients: Natural history, biology and prognosis","volume":"28","author":"Oliveira","year":"2022","journal-title":"Pulmonology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.esmoop.2020.100045","article-title":"Genomic profiling in non-small-cell lung cancer in young patients. A systematic review","volume":"6","author":"Higuera","year":"2021","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ruiz, R., Galvez-Nino, M., Roque, K., Montes, J., Nu\u00f1ez, M., Raez, L., S\u00e1nchez-Gambetta, S., Ja\u00faregui, S., Viale, S., and Smith, E.S. (2022). Genomic landscape of lung cancer in the young. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.910117"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00432-019-03116-6","article-title":"Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes","volume":"146","author":"Tian","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","article-title":"How the ageing microenvironment influences tumour progression","volume":"20","author":"Fane","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41590-024-01828-7","article-title":"The aged tumor microenvironment limits T cell control of cancer","volume":"25","author":"Chen","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00432-022-04195-8","article-title":"Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma","volume":"149","author":"Li","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JCMA.0000000000000311","article-title":"Non\u2013small cell lung cancer in the very young: Higher EGFR\/ALK mutation proportion than the elder","volume":"83","author":"He","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34923","DOI":"10.18632\/oncotarget.16823","article-title":"Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forth-coming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Frcs","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.xcrm.2023.101078","article-title":"Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers","volume":"4","author":"Luo","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.21037\/tlcr-23-577","article-title":"Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: A Chinese, multicenter, real-world cohort study","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK -Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhao, M., Shao, T., Shao, H., Zhou, C., and Tang, W. (2024). Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: A systematic review and network meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11916-4"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cllc.2022.12.003","article-title":"Comparison of Chemotherapy Plus Pem-brolizumab vs. Chemo-therapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients","volume":"24","author":"Chen","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","article-title":"Association Between Age and Survival Trends in Advanced Non\u2013Small Cell Lung Cancer After Adoption of Immunotherapy","volume":"9","author":"Voruganti","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110100","DOI":"10.1016\/j.celrep.2021.110100","article-title":"Pan-cancer analy-sis reveals molecular patterns associated with age","volume":"37","author":"Shah","year":"2021","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.cllc.2016.03.004","article-title":"Assessment of Selection Criteria for Low-Dose Lung Screening CT Among Asian Ethnic Groups in Taiwan: From Mass Screening to Specific Risk-Based Screening for Non-Smoker Lung Cancer","volume":"17","author":"Wu","year":"2016","journal-title":"Clin. Lung Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/489\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:41Z","timestamp":1760035001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090489"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090489","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}